Refractory myasthenia gravis (MG): treatment
Evidence-based neurology checklist on refractory myasthenia gravis (mg): treatment: Plasma exchange (PE) This is a conventional treatment for refractory MG It is also used to achieve remission pre-surgery Intravenous immunoglobulins (IVIg) Rituximab Eculizumab Ravalizumab Emerging treatments
Plasma exchange (PE)
- This is a conventional treatment for refractory MG
- It is also used to achieve remission pre-surgery
Intravenous immunoglobulins (IVIg)
Rituximab
Eculizumab
Ravalizumab
Emerging treatments
References
- Yamada C, Teener JW, Davenport RD, Cooling L. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients. J Clin Apher 2015; 30:314-319.
- Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Neurology 2017; 89:1135-1141.
- Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. JNNP 2020; 91:392-395.
- Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87:419-425.
- Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. JNNP 2011; 82:671-673.
- And 32 more. Subscribe to see the full list
